EGFR and non-small cell lung carcinoma: However, most NSCLC patients develop acquired resistance to 1st-generation TKIs within 10-16 months, in which the EGFR T790M mutation accounts for approximately 50% of all 1st-generation EGFR TKI resistance [9,11].